TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

S Gadgeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.